A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis
The purpose of this study is to learn more about psoriasis in children and how a foam treatment acts on the body and scalp.
Male or female children, ages 2 to 11 years, with mild to moderate plaque psoriasis of the face and scalp.
2 - 11
Healthy Volunteers Needed
Duration of Participation
9 - 13 weeks
Liz Stoos at 503-418-9386
Mayne Pharma Inc.
There will be no cost to subjects or their insurance company for study drug, study visits, and tests done for this study. If subjects qualify for the study, they will receive $50 for the screening visit plus $50 for each of the 3 study visits, for a total of $200. If subjects do not complete the study for any reason, they will be paid only for the visits they do complete.